
Compartir
Título
Prevention of severe vestibular hypofunction after systemic gentamicin
Autor(es)
Palabras clave
Systemic gentamicin
Infective endocarditis
Vestibular hypofunction
Oscillopsia
Video head impulse test
Fecha de publicación
2022
Editor
MDPI
Citación
Ferreira-Cendon, S., Martinez-Carranza, R., Fernandez-Nava, M. J., Villaoslada-Fuente, R., Sanchez-Gomez, H., Cruz-Ruiz, S. S., Sanchez-Ledesma, M., & Batuecas-Caletrio, A. (2022). Prevention of Severe Vestibular Hypofunction after Systemic Gentamicin. Journal of Clinical Medicine, 11(3). https://doi.org/10.3390/JCM11030586
Resumen
[EN]Abstract: The importance of early evaluation by a neurotologist in patients with infective endocarditis
treated with systemic gentamicin and its impact on the patients’ quality of life was evaluated. This
is a longitudinal retrospective cohort study of 29 patients who received intravenous gentamicin
for the treatment of infective endocarditis. Patients were classified into two groups: group A,
before a neurotologist was included in the treatment protocol, and group B, after the inclusion of a
neurotologist. The frequency of the different symptoms in each group was measured, and the gain of
the vestibulo-ocular reflex (VOR) and its relationship with the presence of oscillopsia. In total, 13 and
16 patients were assigned to groups A and B, respectively. The mean gain of the VOR measured using
the video head impulse test in group A was 0.44 in the best side and 0.39 in the worst side. In group
B, the mean gain was 0.71 (best side) and 0.64 (worst side) (p < 0.0001). The patients who complained
about oscillopsia had a main gain of 0.41 in the best side and 0.35 in the worst side. Evaluation of
vestibular function should be included in the infective endocarditis treatment protocol, including the
adverse effects of systemic gentamicin.
URI
DOI
10.3390/jcm11030586
Versión del editor
Aparece en las colecciones












